About The Study: In this study of discharge prescription of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) among patients hospitalized for heart failure, prescription rates increased substantially within 2 years after publication of clinical trial evidence documenting benefit, although considerable variation in rates was found, highlighting the need to understand strategies used by higher prescribing centers to increase SGLT2i adoption.
Corresponding Author: To contact the corresponding author, Mohammad Abdel Jawad, MD, email abdeljawadmd@gmail.com .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.4489)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Heart Association’s Scientific Sessions 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4489?guestAccessKey=035fde61-fae7-4073-90da-14cd7c2a712d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824
JAMA Cardiology